Cover Image
市場調查報告書

Profectus BioSciences, Inc. : 產品平台分析

Profectus BioSciences, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 342297
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Profectus BioSciences, Inc. : 產品平台分析 Profectus BioSciences, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月30日 內容資訊: 英文 48 Pages
簡介

Profectus BioSciences, Inc. 是設計、開發預防及治療疫苗的臨床階段的生物科技企業。該公司還開發基於變遷狀態疫苗的HIV疫苗。

本報告提供Profectus BioSciences, Inc.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估相關資訊等。

Profectus BioSciences, Inc.的基本資料

  • Profectus BioSciences, Inc.概要
  • 主要資訊
  • 企業資料

Profectus BioSciences, Inc.:R&D概要

  • 主要的治療範圍

Profectus BioSciences, Inc.:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Profectus BioSciences, Inc.:開發中產品概況

  • 臨床實驗階段開發中產品
    • 第一階段產品/聯合治療模式
  • 初期階段開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Profectus BioSciences, Inc.:藥物簡介

Profectus BioSciences, Inc.:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型

Profectus BioSciences, Inc.:最近的開發平台趨勢

Profectus BioSciences, Inc.:總公司和子公司的所在地

  • 總公司
  • 其他據點及子公司

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08043CDB

Summary

Global Markets Direct's, 'Profectus BioSciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Profectus BioSciences, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Profectus BioSciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Profectus BioSciences, Inc.
  • The report provides overview of Profectus BioSciences, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Profectus BioSciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Profectus BioSciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Profectus BioSciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Profectus BioSciences, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Profectus BioSciences, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Profectus BioSciences, Inc. Snapshot
    • Profectus BioSciences, Inc. Overview
    • Key Information
    • Key Facts
  • Profectus BioSciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Profectus BioSciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Profectus BioSciences, Inc. - Pipeline Products Glance
    • Profectus BioSciences, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Profectus BioSciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Profectus BioSciences, Inc. - Drug Profiles
    • (Ebola + Marburg) (monovalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (Ebola + Marburg) (trivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIV [strain C1086] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIV-1 vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IHV-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (nipah + hendra) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chikungunya vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • equine encephalitis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis C vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus (7-valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-102.4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lassa fever vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • respiratory syncytial virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Profectus BioSciences, Inc. - Pipeline Analysis
    • Profectus BioSciences, Inc. - Pipeline Products by Target
    • Profectus BioSciences, Inc. - Pipeline Products by Route of Administration
    • Profectus BioSciences, Inc. - Pipeline Products by Molecule Type
  • Profectus BioSciences, Inc. - Recent Pipeline Updates
  • Profectus BioSciences, Inc. - Dormant Projects
  • Profectus BioSciences, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Profectus BioSciences, Inc., Key Information
  • Profectus BioSciences, Inc., Key Facts
  • Profectus BioSciences, Inc. - Pipeline by Indication, 2016
  • Profectus BioSciences, Inc. - Pipeline by Stage of Development, 2016
  • Profectus BioSciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Profectus BioSciences, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Profectus BioSciences, Inc. - Partnered Products in Pipeline, 2016
  • Profectus BioSciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Profectus BioSciences, Inc. - Phase I, 2016
  • Profectus BioSciences, Inc. - Preclinical, 2016
  • Profectus BioSciences, Inc. - Discovery, 2016
  • Profectus BioSciences, Inc. - Pipeline by Target, 2016
  • Profectus BioSciences, Inc. - Pipeline by Route of Administration, 2016
  • Profectus BioSciences, Inc. - Pipeline by Molecule Type, 2016
  • Profectus BioSciences, Inc. - Recent Pipeline Updates, 2016
  • Profectus BioSciences, Inc. - Dormant Developmental Projects,2016
  • Profectus BioSciences, Inc., Other Locations

List of Figures

  • Profectus BioSciences, Inc. - Pipeline by Top 10 Indication, 2016
  • Profectus BioSciences, Inc. - Pipeline by Stage of Development, 2016
  • Profectus BioSciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Profectus BioSciences, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Profectus BioSciences, Inc. - Pipeline by Top 10 Target, 2016
  • Profectus BioSciences, Inc. - Pipeline by Top 10 Molecule Type, 2016
Back to Top